The g-protein coupled receptors market size has grown strongly in recent years. It will grow from $3.4 billion in 2025 to $3.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to neurotransmitter research growth, receptor biology advancements, pharmaceutical R&D expansion, cell line development, assay technology innovation.
The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.77 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to precision drug targeting demand, AI-driven drug discovery, biologics pipeline growth, receptor deorphanization research, investment in translational research. Major trends in the forecast period include rising use of GPCR targets in drug discovery, expansion of high-throughput screening, increased focus on orphan receptor research, growth of cell-based assay technologies, increased academic and pharmaceutical collaboration.
The rising prevalence of cancer is expected to drive the growth of the G-protein-coupled receptors (GPCR) market in the coming years. Cancer is a disease in which abnormal cells invade surrounding tissues and proliferate uncontrollably, with the lymphatic and vascular systems serving as additional routes for metastasis. GPCRs regulate key processes that define cancer, including proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and the initiation of invasion and metastasis. For example, in January 2023, the American Cancer Society, a US-based professional organization, reported that 1,958,310 new cancer cases were diagnosed in the United States in 2023, up from an estimated 1.9 million new cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the G-protein-coupled receptors market.
Key companies in the GPCR market are leveraging Initial Public Offerings (IPOs) to fund the development of drugs targeting G-protein-coupled receptors, aiming to accelerate R&D, advance clinical trials, and bring innovative therapies to patients for a range of diseases, including cancer, neurological disorders, and metabolic conditions. The capital raised is primarily used to advance lead product candidates targeting chronic metabolic and pulmonary diseases, particularly programs focused on glucagon-like peptide-1 receptor (GLP-1R) agonists for diabetes and obesity treatment. For instance, in February 2023, Structure Therapeutics Inc., a US-based company, completed its IPO, raising $161 million to support the development of GPCR-based therapeutics. The company offered 10,740,000 American depositary shares (ADSs) at $15.0 per ADS, exceeding initial projections. The shares began trading on the Nasdaq Global Market under the ticker symbol "GPCR."
In December 2023, Danaher Corporation, a US-based company, acquired Abcam Plc for an undisclosed amount. Through this acquisition, Danaher aims to expand its portfolio by integrating Abcam’s expertise in providing G-protein-coupled receptors (GPCR). Abcam Plc is a UK-based company specializing in GPCR products.
Major companies operating in the g-protein coupled receptors market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Structure Therapeutics, Septerna.
North America was the largest region in the G-protein coupled receptors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g-protein coupled receptors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-protein coupled receptors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the g-protein coupled receptors market by increasing costs of imported cell lines, assay kits, reagents, and analytical instruments. Pharmaceutical companies and research institutes are most affected due to reliance on imported research tools. These tariffs raise R&D costs by increasing expenses for target validation, screening assays, and drug discovery workflows, potentially slowing early-stage research. However, they encourage local production of laboratory reagents, supporting regional capabilities in assay development and research tool manufacturing.
The g-protein coupled receptors market research report is one of a series of new reports that provides g-protein coupled receptors market statistics, including g-protein coupled receptors industry global market size, regional shares, competitors with a g-protein coupled receptors market share, detailed g-protein coupled receptors market segments, market trends and opportunities, and any further data you may need to thrive in the g-protein coupled receptors industry. This g-protein coupled receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
G-protein coupled receptors (GPCRs) are a type of membrane receptor, also known as seven-(pass)-transmembrane receptors. They are located in the cell membrane and are responsible for binding extracellular molecules and transmitting signals from these substances to intracellular targets. GPCRs represent the largest family of membrane proteins, mediating most cellular responses to hormones and neurotransmitters, and play key roles in vision, olfaction, and taste.
The main products related to G-protein-coupled receptors include cell lines, detection kits, cell culture reagents, and ligands. A cell line is a culture of cells selected for uniformity from a population derived from a typically homogeneous tissue source. The various types of assays include cAMP functional assays, calcium functional assays, β-arrestin functional assays, radioligand binding and GTPγS functional assays, internalization assays, and trafficking assays. These products and assays are used in a wide range of applications, including cancer research, CNS research, metabolic research, cardiovascular research, inflammation research, respiratory research, and others.
The G-protein-coupled receptors market consists of revenues earned by entities by providing GPCR screening and profiling services, GPCR antibodies and immunoassays, hormones visual control. The market value includes the value of related goods sold by the service provider or included within the service offering. The G-protein-coupled receptors market also includes sales of adenosine, serotonin, and metabotropic receptor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.77 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to precision drug targeting demand, AI-driven drug discovery, biologics pipeline growth, receptor deorphanization research, investment in translational research. Major trends in the forecast period include rising use of GPCR targets in drug discovery, expansion of high-throughput screening, increased focus on orphan receptor research, growth of cell-based assay technologies, increased academic and pharmaceutical collaboration.
The rising prevalence of cancer is expected to drive the growth of the G-protein-coupled receptors (GPCR) market in the coming years. Cancer is a disease in which abnormal cells invade surrounding tissues and proliferate uncontrollably, with the lymphatic and vascular systems serving as additional routes for metastasis. GPCRs regulate key processes that define cancer, including proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and the initiation of invasion and metastasis. For example, in January 2023, the American Cancer Society, a US-based professional organization, reported that 1,958,310 new cancer cases were diagnosed in the United States in 2023, up from an estimated 1.9 million new cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the G-protein-coupled receptors market.
Key companies in the GPCR market are leveraging Initial Public Offerings (IPOs) to fund the development of drugs targeting G-protein-coupled receptors, aiming to accelerate R&D, advance clinical trials, and bring innovative therapies to patients for a range of diseases, including cancer, neurological disorders, and metabolic conditions. The capital raised is primarily used to advance lead product candidates targeting chronic metabolic and pulmonary diseases, particularly programs focused on glucagon-like peptide-1 receptor (GLP-1R) agonists for diabetes and obesity treatment. For instance, in February 2023, Structure Therapeutics Inc., a US-based company, completed its IPO, raising $161 million to support the development of GPCR-based therapeutics. The company offered 10,740,000 American depositary shares (ADSs) at $15.0 per ADS, exceeding initial projections. The shares began trading on the Nasdaq Global Market under the ticker symbol "GPCR."
In December 2023, Danaher Corporation, a US-based company, acquired Abcam Plc for an undisclosed amount. Through this acquisition, Danaher aims to expand its portfolio by integrating Abcam’s expertise in providing G-protein-coupled receptors (GPCR). Abcam Plc is a UK-based company specializing in GPCR products.
Major companies operating in the g-protein coupled receptors market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Structure Therapeutics, Septerna.
North America was the largest region in the G-protein coupled receptors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g-protein coupled receptors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-protein coupled receptors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the g-protein coupled receptors market by increasing costs of imported cell lines, assay kits, reagents, and analytical instruments. Pharmaceutical companies and research institutes are most affected due to reliance on imported research tools. These tariffs raise R&D costs by increasing expenses for target validation, screening assays, and drug discovery workflows, potentially slowing early-stage research. However, they encourage local production of laboratory reagents, supporting regional capabilities in assay development and research tool manufacturing.
The g-protein coupled receptors market research report is one of a series of new reports that provides g-protein coupled receptors market statistics, including g-protein coupled receptors industry global market size, regional shares, competitors with a g-protein coupled receptors market share, detailed g-protein coupled receptors market segments, market trends and opportunities, and any further data you may need to thrive in the g-protein coupled receptors industry. This g-protein coupled receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
G-protein coupled receptors (GPCRs) are a type of membrane receptor, also known as seven-(pass)-transmembrane receptors. They are located in the cell membrane and are responsible for binding extracellular molecules and transmitting signals from these substances to intracellular targets. GPCRs represent the largest family of membrane proteins, mediating most cellular responses to hormones and neurotransmitters, and play key roles in vision, olfaction, and taste.
The main products related to G-protein-coupled receptors include cell lines, detection kits, cell culture reagents, and ligands. A cell line is a culture of cells selected for uniformity from a population derived from a typically homogeneous tissue source. The various types of assays include cAMP functional assays, calcium functional assays, β-arrestin functional assays, radioligand binding and GTPγS functional assays, internalization assays, and trafficking assays. These products and assays are used in a wide range of applications, including cancer research, CNS research, metabolic research, cardiovascular research, inflammation research, respiratory research, and others.
The G-protein-coupled receptors market consists of revenues earned by entities by providing GPCR screening and profiling services, GPCR antibodies and immunoassays, hormones visual control. The market value includes the value of related goods sold by the service provider or included within the service offering. The G-protein-coupled receptors market also includes sales of adenosine, serotonin, and metabotropic receptor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. G-Protein Coupled Receptors Market Characteristics
3. G-Protein Coupled Receptors Market Supply Chain Analysis
4. Global G-Protein Coupled Receptors Market Trends and Strategies
5. G-Protein Coupled Receptors Market Analysis of End Use Industries
7. Global G-Protein Coupled Receptors Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global G-Protein Coupled Receptors Total Addressable Market (TAM) Analysis for the Market
9. G-Protein Coupled Receptors Market Segmentation
10. G-Protein Coupled Receptors Market Regional and Country Analysis
11. Asia-Pacific G-Protein Coupled Receptors Market
12. China G-Protein Coupled Receptors Market
13. India G-Protein Coupled Receptors Market
14. Japan G-Protein Coupled Receptors Market
15. Australia G-Protein Coupled Receptors Market
16. Indonesia G-Protein Coupled Receptors Market
17. South Korea G-Protein Coupled Receptors Market
18. Taiwan G-Protein Coupled Receptors Market
19. South East Asia G-Protein Coupled Receptors Market
20. Western Europe G-Protein Coupled Receptors Market
21. UK G-Protein Coupled Receptors Market
22. Germany G-Protein Coupled Receptors Market
23. France G-Protein Coupled Receptors Market
24. Italy G-Protein Coupled Receptors Market
25. Spain G-Protein Coupled Receptors Market
26. Eastern Europe G-Protein Coupled Receptors Market
27. Russia G-Protein Coupled Receptors Market
28. North America G-Protein Coupled Receptors Market
29. USA G-Protein Coupled Receptors Market
30. Canada G-Protein Coupled Receptors Market
31. South America G-Protein Coupled Receptors Market
32. Brazil G-Protein Coupled Receptors Market
33. Middle East G-Protein Coupled Receptors Market
34. Africa G-Protein Coupled Receptors Market
36. G-Protein Coupled Receptors Market Competitive Landscape and Company Profiles
37. G-Protein Coupled Receptors Market Other Major and Innovative Companies
40. G-Protein Coupled Receptors Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
G-Protein Coupled Receptors Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses g-protein coupled receptors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for g-protein coupled receptors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The g-protein coupled receptors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Cell Lines; Detection Kits; Cell Culture Reagents; Ligands2) By Assay: CAMP Functional Assays; Calcium Functional Assays; β-Arrestin Functional Assays; Radioligand Binding And GTPγS Functional Assays; Internalization Assays; Trafficking Assays
3) By Applications: Cancer Research; CNS Research; Metabolic Research; Cardiovascular Research; Inflammation Research; Respiratory Research; Other Applications
Subsegments:
1) By Cell Lines: GPCR-Expressing Cell Lines; Stable And Transient Cell Lines2) By Detection Kits: ELISA Kits; High-Throughput Screening Kits; Reporter Gene Assays
3) By Cell Culture Reagents: Media And Supplements; Transfection Reagents; Growth Factors
4) By Ligands: Agonists; Antagonists; Inverse Agonists
Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer AG; Novartis International AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca Plc; GlaxoSmithKline Plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Merck KGaA; Boehringer Ingelheim; Daiichi Sankyo Company Limited; Danaher Corporation; Thermo Fisher Scientific Inc.; PerkinElmer Inc.; Bio-Techne Corporation; Abcam PLC; Cara Therapeutics Inc.; Sosei Heptares Ltd.; Eurofins DiscoverX Corporation; Crinetics Pharmaceuticals Inc.; Domain Therapeutics SA; Addex Pharmaceuticals Ltd.; Structure Therapeutics; Septerna
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this G-Protein Coupled Receptors market report include:- Pfizer Inc.
- Roche Holding AG
- AbbVie Inc.
- Bayer AG
- Novartis International AG
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca Plc
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Merck KGaA
- Boehringer Ingelheim
- Daiichi Sankyo Company Limited
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- Bio-Techne Corporation
- Abcam PLC
- Cara Therapeutics Inc.
- Sosei Heptares Ltd.
- Eurofins DiscoverX Corporation
- Crinetics Pharmaceuticals Inc.
- Domain Therapeutics SA
- Addex Pharmaceuticals Ltd.
- Structure Therapeutics
- Septerna
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.63 Billion |
| Forecasted Market Value ( USD | $ 4.77 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
